Mark Berger
Chief Tech/Sci/R&D Officer at GENPREX, INC.
Net worth: 10 189 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ryan Confer | M | 42 | 13 years | |
Harlan Waksal | M | 71 |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 10 years |
Jose Antonio Moreno Toscano | M | 51 | 4 years | |
Avinash Desai | M | - | 4 years | |
William Wilson | M | 74 | 4 years | |
Jeffrey Chell | M | 70 | 6 years | |
Kalyn Dabbs | M | - | 5 years | |
Ajit Shetty | M | 77 | 7 years | |
Brent Longnecker | M | 67 | 4 years | |
Bart M. Schwartz | M | 77 |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 9 years |
Thomas C. Gallagher | M | - | 4 years | |
David Schloss | M | 65 | 4 years | |
Anastasios Konidaris | M | 57 |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 7 years |
Mary Mei Chen | M | - | 4 years | |
Paul Diamond | M | - | 3 years | |
Celina Laney | F | - | 6 years | |
Greg Jancarik | M | - | 3 years | |
Kate Combs | F | - | 3 years | |
Suzanne Thornton-Jones | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kaushik J. Dave | M | 63 | 4 years | |
J. Varner | M | 67 | 15 years | |
Sergio Traversa | M | 63 | 4 years | |
Dragan Cicic | M | 60 | 12 years | |
Moncef Slaoui | M | 64 | 11 years | |
Samuel D. Waksal | M | - |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | - |
Robert Wilson | M | 81 | 11 years | |
Catherine Vaczy | F | 62 | 5 years | |
Daniel Podolsky | M | 70 | 10 years | |
Alex Howarth | M | 55 | 10 years | |
Tom de Swaan | M | 78 | 9 years | |
Crispin Davis | M | 75 | 10 years | |
Michèle Barzach | M | - | 7 years | |
John David Coombe | M | 79 | 5 years | |
Christopher Gent | M | 75 | 11 years | |
Patrick J. T. Vallance | M | 64 | - | |
Deryck Charles Maughan | M | 76 | 12 years | |
Peter Traber | M | 69 | 3 years | |
H. Culp | M | 60 | 9 years | |
Jeannine Larrieux | M | - | 3 years | |
Chao Hong Hu | M | 58 | 1 years | |
Zhen Ping Zhu | M | 59 |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 6 years |
Tonya Williams | F | 50 | 1 years | |
Bing Li | M | 55 | 4 years | |
David Wheadon | M | 66 | 5 years | |
John Clarke | M | - | - | |
Robert Copeland | M | - | - | |
Hemant Kumar | M | 61 | 2 years | |
James Wu | M | - | 10 years | |
Eva Heyman | F | - |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | - |
Jing Ji | M | 54 | 4 years | |
Michael Allen Luther | M | 67 | 15 years | |
Alasdair B. James | M | 53 | 6 years | |
Vincent O'Neill | M | 55 | 3 years | |
David Gordon | M | 55 | 11 years | |
Manuel Alves Aivado | M | 53 | 6 years | |
Johan Heylen | M | 56 | 4 years | |
Brian Blakey | M | 61 | 6 years | |
Joe McCann | M | 47 | 4 years | |
Vivid Sehgal | M | 56 | 6 years | |
Shannon Inman | F | - | 1 years | |
Gill Dines | F | - | - | |
Myra Rosario Herrle | M | - | 9 years | |
Stewart Mccallum | M | 58 | 9 years | |
Maria Gomes Nunes | M | - | 4 years | |
Vijay Reddy | M | - | 4 years | |
Niva Almaula | M | - | - | |
Neil Brewis | M | 57 | 8 years | |
Marc Rubin | M | 69 | 13 years | |
Denis Brodsky | M | 53 | 5 years | |
Lucy Shapiro | M | 83 | 5 years | |
Fred Banti | M | 67 |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | 2 years |
Walter W. Witoshkin | M | 78 | 2 years | |
Joseph M. Spagnardi | M | 60 | 11 years | |
M. Berrey | M | 57 | 3 years | |
Michael D. Rogers | M | 68 | 6 years | |
Paul A. Allaire | M | - | - | |
Donald F. McHenry | M | 87 | - | |
John Hector McArthur | M | 90 | - | |
Timothy Barberich | M | 76 |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | 4 years |
Howard H. Pien | M | 66 | 12 years | |
Michael T. Redman | M | 69 | 2 years | |
F. Roger Hurn | M | 86 | - | |
Christopher Anthony Hogg | M | - | - | |
Stephen A. Ross | M | 54 | 5 years | |
Robert J. DiVasto | M | 68 | 2 years | |
David Gould | M | - | 7 years | |
Dan A. Giampuzzi | M | - |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | 9 years |
Lisa Porter | M | 60 | 5 years | |
Gary W. Christianson | M | 69 | 2 years | |
Jennie Younger | F | - | 5 years | |
John B. Ziegler | M | 78 | - | |
Jeff Baxter | M | 62 | 4 years | |
Atul Pande | M | 69 | 7 years | |
Eric Roberts | M | 59 |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | 4 years |
Jean Viallet | M | 66 |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | 9 years |
Paul Carter | M | 63 | 10 years | |
Lauren Flanagan | F | - | - | |
Sheng Da Zan | M | 61 |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | - |
Anil Kapur | M | 54 | 1 years | |
K Fletcher | M | - |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 57 | 57.00% |
United States | 43 | 43.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Berger
- Personal Network